New pooled phase 3 and extension trial data show odevixibat continues to improve disease management and itch reduction in children with Alagille syndrome.
Ipsen drug Bylvay is now FDA approved for treating pruritus, or severe itching, which is a complication of the rare liver disease Alagille syndrome. The oral drug was previously approved for treating pruritus in another rare inherited liver disease called PFIC.
Six abstracts to be presented demonstrating efficacy and tolerability of investigational Bylvay in select cholestatic liver diseasesNew data emphasizes the consistent benefit of Bylvay as an. | May 17, 2023
Six abstracts to be presented demonstrating efficacy and tolerability of investigational Bylvay in select cholestatic liver diseasesNew data emphasizes the consistent benefit of Bylvay as an investigational
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced